Price
Financials
Consolidated, Rs crore| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 440 | 449 | 506 | 555 | 458 | 538 | 564 | 386 | 418 | 432 | 583 | 536 |
| Expenses | 352 | 353 | 388 | 459 | 364 | 409 | 418 | 293 | 344 | 330 | 470 | 400 |
| Operating Profit | 88 | 96 | 118 | 96 | 94 | 129 | 146 | 93 | 74 | 102 | 113 | 136 |
| OPM % | 20% | 21% | 23% | 17% | 20% | 24% | 26% | 24% | 18% | 24% | 19% | 25% |
| Other Income | 1 | 1 | 2 | 2 | 4 | 5 | -2 | 2 | 0 | 2 | 14 | 8 |
| Interest | 4 | 4 | 5 | 5 | 6 | 10 | 7 | 7 | 11 | 13 | 17 | 13 |
| Depreciation | 18 | 19 | 19 | 20 | 21 | 23 | 23 | 23 | 25 | 29 | 28 | 30 |
| Profit before tax | 67 | 74 | 96 | 74 | 72 | 101 | 115 | 65 | 39 | 63 | 82 | 101 |
| Tax % | 23% | 29% | 32% | 25% | 24% | 26% | 23% | 24% | 28% | 24% | 25% | 25% |
| Net Profit | 52 | 53 | 65 | 55 | 55 | 74 | 88 | 50 | 28 | 48 | 61 | 76 |
| EPS in Rs | 5.72 | 5.82 | 7.20 | 6.12 | 6.03 | 8.16 | 9.75 | 5.46 | 3.08 | 5.29 | 6.74 | 8.40 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM | |
|---|---|---|---|---|---|---|---|
| Sales | 0 | 1,200 | 1,945 | 1,853 | 2,115 | 1,819 | 1,969 |
| Expenses | 0 | 993 | 1,603 | 1,467 | 1,649 | 1,450 | 1,543 |
| Operating Profit | 0 | 207 | 342 | 386 | 466 | 369 | 426 |
| OPM % | 17% | 18% | 21% | 22% | 20% | 22% | |
| Other Income | 0 | 3 | 2 | 5 | 8 | 15 | 23 |
| Interest | 0 | 12 | 21 | 17 | 27 | 47 | 53 |
| Depreciation | 0 | 42 | 63 | 73 | 87 | 104 | 112 |
| Profit before tax | 0 | 155 | 261 | 300 | 361 | 233 | 284 |
| Tax % | 21% | 26% | 28% | 24% | 25% | ||
| Net Profit | 0 | 122 | 193 | 217 | 272 | 175 | 213 |
| EPS in Rs | 21.35 | 23.93 | 30.05 | 19.27 | 23.51 | ||
| Dividend Payout % | 0% | 9% | 13% | 17% | 18% |
| 10 Years | 5 Years | 3 Years | TTM | 1 Year | Last Year | |
|---|---|---|---|---|---|---|
| Compounded Sales Growth | % | % | -2% | 1% | ||
| Compounded Profit Growth | % | % | -3% | -19% | ||
| Stock Price CAGR | % | % | 28% | 18% | ||
| Return on Equity | % | 13% | 12% | 9% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Equity Capital | 0.25 | 0.25 | 45 | 45 | 45 | 45 |
| Reserves | -0 | 1,386 | 1,513 | 1,712 | 1,945 | 2,079 |
| Borrowings | 0 | 338 | 215 | 285 | 413 | 754 |
| Other Liabilities | 0 | 315 | 470 | 540 | 499 | 603 |
| Total Liabilities | 0 | 2,040 | 2,244 | 2,582 | 2,902 | 3,482 |
| Fixed Assets | 0 | 782 | 926 | 1,033 | 1,137 | 1,437 |
| CWIP | 0 | 187 | 102 | 137 | 374 | 393 |
| Investments | 0 | 32 | 87 | 107 | 77 | 194 |
| Other Assets | 0 | 1,038 | 1,130 | 1,305 | 1,315 | 1,457 |
| Total Assets | 0 | 2,040 | 2,244 | 2,582 | 2,902 | 3,482 |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Cash from Operating Activity | 0 | -44 | 250 | 216 | 330 | 262 |
| Cash from Investing Activity | 0 | -139 | -158 | -215 | -412 | -431 |
| Cash from Financing Activity | 0 | 260 | -163 | 10 | 65 | 171 |
| Net Cash Flow | 0 | 78 | -71 | 12 | -17 | 2 |
| Free Cash Flow | 0 | -185 | 130 | 18 | -114 | -186 |
| CFO/OP | -11% | 91% | 71% | 85% | 84% |
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|
| Debtor Days | 115 | 84 | 102 | 99 | 117 | |
| Inventory Days | 272 | 188 | 230 | 199 | 280 | |
| Days Payable | 123 | 106 | 135 | 94 | 146 | |
| Cash Conversion Cycle | 264 | 166 | 197 | 204 | 251 | |
| Working Capital Days | 111 | 94 | 110 | 105 | 90 | |
| ROCE % | 19% | 16% | 17% | 17% | 11% |
| Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promoters | 46.30% | 46.46% | 46.46% | 46.46% | 46.10% | 44.65% | 44.29% | 43.72% | 42.88% | 43.10% | 43.08% | 42.86% |
| FIIs | 8.45% | 8.17% | 8.33% | 7.07% | 7.38% | 8.64% | 7.36% | 7.34% | 8.02% | 7.69% | 8.39% | 8.17% |
| DIIs | 10.51% | 9.91% | 9.97% | 11.47% | 11.35% | 10.36% | 7.53% | 7.80% | 6.95% | 7.66% | 7.40% | 7.22% |
| Government | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% | 0.01% |
| Public | 34.73% | 35.45% | 35.24% | 35.00% | 35.17% | 36.33% | 40.81% | 41.12% | 42.12% | 41.54% | 41.10% | 41.74% |
| No. of Shareholders | 2,26,286 | 2,15,796 | 2,04,122 | 1,89,012 | 1,85,436 | 1,85,111 | 1,96,314 | 1,87,039 | 1,90,655 | 1,84,489 | 1,79,373 | 1,76,506 |
Fundamentals
Market Cap₹ 8,821 Cr.
Current Price₹ 973
Stock P/E41.0
Book Value₹ 234
ROCE10.7 %
ROE8.59 %
Dividend Yield0.36 %
Face Value₹ 5.00
Compounded Sales Growth (TTM)1%
Compounded Profit Growth (TTM)-19%
Consolidated figures.
Valuation
Market capRs 8,782 Cr
Enterprise valueRs 9,037 Cr
P/E (TTM)41.20x
Price to book6.33x
Price to sales4.46x
EV / EBITDA20.13x
EV / EBIT26.79x
EV / sales4.59x
Earnings yield2.43%
Profitability
Operating margin (excl. other income)17.25%
Operating margin (incl. other income)17.46%
EBITDA margin22.80%
Pre-tax margin14.44%
Net profit margin10.82%
Net margin, latest quarter14.21%
ROE17.63%
ROCE19.40%
ROA11.98%
ROIC (approx.)16.17%
Tax rate21.32%
Other income / net worth0.18%
Growth
Sales growth QoQ-8.04%
Profit growth QoQ24.57%
Sales growth YoY (latest quarter)38.74%
Profit growth YoY (latest quarter)53.82%
Per share
EPS (TTM)Rs 23.50
EPS (latest year)Rs 4,890.00
EPS (latest quarter)Rs 8.40
Book value per shareRs 152.90
Sales per shareRs 217.14
Cash flow per shareRs -4.82
Free cash flow per shareRs -20.51
Efficiency
Asset turnover0.59x
Fixed asset turnover1.53x
Inventory turnover1.85x
Inventory days197 days
Debtor days115 days
Debtors turnover3.19x
Creditor days146 days
Cash conversion cycle251 days
Working capital days90 days
Leverage
Total debtRs 338 Cr
Cash and bankRs 83 Cr
Net debtRs 255 Cr
Debt to equity0.24x
Net debt / EBITDA0.57x
Interest coverage6.37x
Current ratio (filing 2026-03-31)1.49x
Quick ratio (filing 2026-03-31)0.81x
Trade payables (filing 2026-03-31)Rs 335 Cr
Owners' fund to total sources67.97%
Debt to assets16.58%
Cash flow
Cash from Operating Activity (latest year)Rs -44 Cr
Cash from Investing Activity (latest year)Rs -139 Cr
Cash from Financing Activity (latest year)Rs 260 Cr
Net Cash Flow (latest year)Rs 78 Cr
Free cash flow (latest year)Rs -186 Cr
FCFE (approx.: FCF + change in debt)Rs 152 Cr
Cash from ops / profit, 5 years1.04x
Statement figures
Net sales (TTM)Rs 1,969 Cr
Net sales (latest year)Rs 1,200 Cr
Sales (latest quarter)Rs 536 Cr
Operating profit excl. other income (latest year)Rs 207 Cr
Operating profit (latest quarter)Rs 136 Cr
Other income (TTM)Rs 23 Cr
EBITDA (TTM)Rs 449 Cr
PBDT (TTM)Rs 396 Cr
Profit before tax (TTM)Rs 284 Cr
Tax (latest year)Rs 33 Cr
Net profit (TTM)Rs 213 Cr
Net profit (latest year)Rs 122 Cr
Net profit (latest quarter)Rs 76 Cr
Depreciation (TTM)Rs 112 Cr
Depreciation (latest quarter)Rs 30 Cr
Interest (TTM)Rs 53 Cr
Cost of goods sold (latest year)Rs 880 Cr
Total expenditure (latest year)Rs 993 Cr
Total income (latest year)Rs 1,202 Cr
Share capitalRs 0 Cr
ReservesRs 1,386 Cr
Shareholders' fundsRs 1,386 Cr
Total assetsRs 2,040 Cr
Net blockRs 782 Cr
Capital work in progressRs 187 Cr
InvestmentsRs 32 Cr
ReceivablesRs 377 Cr
InventoryRs 475 Cr
Other liabilitiesRs 315 Cr
Shares outstanding (crore)9.07
Ownership
Promoter holding42.86% (-0.86 in a year)
Computed by MarketFriction from the consolidated statements. Returns use average balances.
Not enough history to build valuation bands (needs two years of profits and prices).
| Period | AARTIPHARM | Nifty 50 | Difference |
|---|---|---|---|
| 1 week | +3.7% | -2.8% | +6.4 pts |
| 1 month | +11.9% | -6.8% | +18.7 pts |
| 3 months | +37.1% | -7.6% | +44.7 pts |
| 6 months | +63.6% | +0.4% | +63.2 pts |
| 1 year | +14.8% | -9.9% | +24.8 pts |
| 2 years | +52.2% | -13.6% | +65.8 pts |
| 3 years | +109.7% | +14.2% | +95.5 pts |
15 mutual fund schemes hold about ₹47 Cr.
Over three months 0 bought more and 15 sold (share counts, price move removed).
| Fund | Weight | Est. Cr | 3m shares |
|---|---|---|---|
| UTI Healthcare Fund | 0.88% | 13 | -18% |
| Motilal Oswal Nifty Microcap 250 Index Fund | 0.45% | 11 | -15% |
| WOC Pharma and Healthcare Fund | 1.10% | 10 | -7% |
| HDFC Large & Mid Cap Fund | 0.02% | 6 | -13% |
| Unifi Flexi Cap Fund | 1.52% | 4 | -23% |
| Taurus Flexi Cap Fund | 0.97% | 4 | -17% |
| Groww Nifty Total Market Index Fund | 0.02% | 0 | -10% |
| Bandhan BSE Healthcare Index Fund | 0.27% | 0 | -13% |
| Angel One Nifty Total Market Index Fund | 0.02% | 0 | -10% |
| Mirae Asset Nifty Total Market Index Fund | 0.02% | 0 | -10% |
| Bandhan Nifty Total Market Index Fund | 0.02% | 0 | -10% |
| Motilal Oswal BSE 1000 Index Fund | 0.02% | 0 | -10% |
| ICICI Pru Children's Fund | 0.00% | 0 | -100% |
| ICICI Pru Exports & Services Fund | 0.00% | 0 | -100% |
| ICICI Pru Exports & Services Fund | 0.00% | 0 | -100% |
Red flags
No red flags in the latest statements and filings.
Checks on the latest reported years: cash vs profit, accruals, receivables and inventory vs sales, dilution, debt, interest cover, equity, other income, losses, and auditor, top-management, insolvency and regulator filings in the last 12 months. A flag asks for an explanation; it is not a verdict.
Insider trades
NSE insider and takeover-code disclosures| Date | Who | Role | Side | Shares | Value | How |
|---|---|---|---|---|---|---|
| 2026-09-21 | GLOIRE TRUSTEESHIP SERVICES PVT. L | Promoter group | sell | 624,500 | SAST Open Market |
Latest disclosed trades by insiders, promoters and large holders. Grants, option exercises and pledges show as "other". A filing is a fact, not a signal on its own.
Latest quarter
Jun 2026Sales ₹536 Cr +38.9% vs Jun 2025.
Net profit ₹76 Cr +52.0%.
Against our estimate for Jun 2026: sales +51.2%, profit +98.8% beat. Our estimate for Sep 2026: sales Rs 506 Cr, profit Rs 55 Cr (how).
Activity
Compare| Company | Mcap (Cr) | P/E | ROCE |
|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | 447,476 | 35.4 | 20.5 % |
| Divis Laboratories Ltd | 250,363 | 84.0 | 22.0 % |
| Torrent Pharmaceuticals Ltd | 186,152 | 83.4 | 15.2 % |
| Zydus Lifesciences Ltd | 119,750 | 24.6 | 21.1 % |
| Cipla Ltd | 111,430 | 31.1 | 15.5 % |
| Laurus Labs Ltd | 106,928 | 97.8 | 17.8 % |
| Mankind Pharma Ltd | 105,120 | 49.3 | 13.5 % |
| Dr Reddys Laboratories Ltd | 104,494 | 32.4 | 13.0 % |
| Aurobindo Pharma Ltd | 97,682 | 25.8 | 12.9 % |
| Lupin Ltd | 93,840 | 15.8 | 29.9 % |
| Glenmark Pharmaceuticals Ltd | 68,905 | 22.1 | 39.8 % |
| Alkem Laboratories Ltd | 62,772 | 27.6 | 21.2 % |
| Biocon Ltd | 61,439 | 84.5 | 3.61 % |
| Abbott India Ltd | 57,949 | 35.9 | 44.8 % |
| Gland Pharma Ltd | 49,333 | 43.1 | 15.1 % |
No bulk or block deals on record.
| Ex-date | Action | Factor |
|---|---|---|
| 2026-09-15 | Dividend - Rs 2 Per Share | |
| 2026-02-16 | Interim Dividend - Rs 1.50 Per Share | |
| 2025-09-15 | Dividend - Rs 2.50 Per Share | |
| 2025-02-14 | Interim Dividend - Rs 2.50 Per Share | |
| 2024-07-31 | Dividend - Re 1 Per Share | |
| 2024-02-16 | Interim Dividend - Rs 2 Per Share |
| Date | Type | What it says |
|---|---|---|
| 2026-09-30 | General Updates | Intimation Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 |
| 2026-09-30 | Updates | Intimation under Regulation 30 of SEBI Listing Regulations- Reconstitution of Committee of the Board of Directors. |
Company filings to NSE, newest first. Routine notices (trading window, newspaper copies) are left out. Click a row for the filing.
No short selling reported to NSE in our files.
Short sales disclosed by brokers to NSE, by trade date. Collected since late September 2026.
Not on any NSE surveillance list in the latest file.
Quick answers
What is the market cap of Aarti Pharmalabs Ltd?
Aarti Pharmalabs Ltd (AARTIPHARM) has a market capitalisation of Rs 8,821 Cr. at the 2026-10-01 close.
What is the P/E ratio of Aarti Pharmalabs Ltd?
Aarti Pharmalabs Ltd trades at a P/E of 41.0 on trailing twelve-month profit, at the 2026-10-01 close.
What were Aarti Pharmalabs Ltd's latest quarterly results?
In the Jun 2026 quarter, Aarti Pharmalabs Ltd sales was Rs 536 Cr (+38.9% vs Jun 2025) and net profit was Rs 76 Cr.
What is the 52-week high and low of Aarti Pharmalabs Ltd?
The 52-week high is Rs 1,002.40 and the 52-week low is Rs 585.00.